SLU PP 332

SLU PP 332 is an experimental small molecule exercise mimetic that activates estrogen-related receptor (ERR) signaling pathways, particularly ERRα, ERRβ, and ERRγ, which play crucial roles in mitochondrial biogenesis and oxidative metabolism. ERRs are key regulators of genes involved in energy production and fatty acid oxidation, normally activated by exercise. Research demonstrates SLU PP 332 increases mitochondrial content, enhances oxidative capacity, improves endurance performance, and promotes fat oxidation in animal models without actual exercise. The compound effectively recapitulates some molecular signatures of endurance training. Studies show potential applications for obesity, metabolic syndrome, muscular dystrophies, and conditions where exercise is limited or impossible. SLU PP 332 represents a novel approach to exercise mimicry distinct from AMPK activators like AICAR. The compound is in early research stages with limited published human data. It holds promise for conditions where exercise prescription is challenging, though questions remain about whether pharmacological exercise mimicry can fully replicate the comprehensive benefits of physical activity.

All evidence is preclinical (rodent); there are no human safety, pharmacokinetic, or efficacy data. Bioavailability and dosing are unresolved, and long-term effects of ERR pathway activation are unknown.

Pan-agonist of estrogen-related receptors (ERRα/β/γ) that drives expression of mitochondrial and oxidative-metabolism genes; in rodent studies typically administered by injection, with poor oral bioavailability reported.